Pfizer Acquires Antibody Discovery and Optimization Company

17-Aug-2005

Pfizer Inc and Bioren Inc announced the completion of a transaction in which Pfizer purchased all outstanding stock of Bioren for an undisclosed amount. Bioren is a California-based, privately held company specializing in technology for optimizing antibodies. Antibody optimization technologies assist drug companies in developing medicines with improved properties such as greater and longer lasting efficacy. Bioren has developed Walk-Through mutagenesis (WTMTM) and Look-Through Mutagenesis (LTMTM) technologies to improve the drug development of antibodies.

Over the last five years Pfizer has made significant internal and external investments, including the acquisition of Bioren, which have resulted in a substantial portfolio of therapeutic proteins and other macromolecules currently in various stages of development.

Other news from the department business & finance

Most read news

More news from our other portals

Fighting cancer: latest developments and advances

See the theme worlds for related content

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous

View topic world

Topic world Antibodies

Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous